RESUMEN

Indomethacin-responsive headaches encompass a group of disorders which include a subset of the trigeminal autonomic cephalalgias and other paroxysmal, often precipitated primary headaches. Many patients show a rapid therapeutic response to indomethacin, which is limited by intolerability. Etoricoxib and celecoxib, selective inhibitors of cyclo-oxygenase-2 (COX-2), spare gastroduodenal COX-1 activity and are less likely to cause gastrointestinal adverse effects than indomethacin. We report a case series of eight patients, seven who responded to etoricoxib and one patient who responded to celecoxib.

Asunto(s)

Trastornos de Cefalalgia , Indometacina , Antiinflamatorios no Esteroideos/farmacología , Celecoxib/efectos adversos , Etoricoxib/uso terapéutico , Cefalea/inducido químicamente , Cefalea/tratamiento farmacológico , Trastornos de Cefalalgia/tratamiento farmacológico , Humanos , Indometacina/efectos adversos